Clinical Trial Update: A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for ICP-022 in systemic lupus erythematosus across Phase 1 and Phase 2 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• ICP-022

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Systemic Lupus Erythematosus | Phase 1, Phase 2 | Status: COMPLETED